Clinical Trial

CLOUD-R HAE REGISTRY

Study acronym: CloudRHAE
Recruiting
View on ClinicalTrials.gov →
Summary
Angioedema is a disease characterized by the appearance of self-limiting edema that last 1-5 days and affect the subcutaneous tissue and/or gastrointestinal and oropharyngeal mucosa. In this last location edema can be lethal causing asphyxia, in all other cases full recovery is complete. Attacks can appear as part of the syndrome urticaria angioedema and can be of allergic origin. But there is a group of non-allergic angioedema that occur without hives and can be either hereditary or acquired. These angioedema are identified in some cases on the basis of etiology, in others are identified by the mediator and an overall classification of these forms of angioedema was published in 2014 as a result of a consent conference organized by the proponents of this registry. Being these forms of angioedema rare, there are not significative case studies inclusive of a high number of patients. This registry aims to collect in a single place a high number of subjects with recurring angioedema and without urticaria.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2019-02-15; most recent amendment 2021-10-29.
Trial Details
NCT Number NCT03845946
Lead Sponsor University Hospital, Grenoble
Conditions ANGIOEDEMA
Enrollment 1,000 participants
Start Date 2018-09-01
Primary Completion 2028-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2021-11-01